z-logo
Premium
Human pegivirus molecular epidemiology in Argentina: Potential contribution of Latin American migration to genotype 3 circulation
Author(s) -
Trinks Julieta,
Maestri Miriam,
Oliveto Fabián,
del Pino Noemí,
Weissenbacher Mercedes,
Torres Oscar Walter,
Oubiña José Raúl
Publication year - 2014
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.23918
Subject(s) - genotype , latin americans , virology , human immunodeficiency virus (hiv) , biology , demography , genetics , gene , linguistics , philosophy , sociology
In order to determine the human pegivirus (HPgV) genotypic diversity in Argentina taking into account the potential contribution of human migration from neighboring countries, samples from 130 Argentine injecting drug users, 116 Argentine‐ and 50 immigrant‐pregnant women were analyzed. HPgV RNA prevalence among human immunodeficiency virus (HIV)‐positive injecting drug users was similar to HIV‐positive pregnant women, as was the case when comparing HIV‐negative injecting drug users and HIV‐negative pregnant women ( P  > 0.05). HPgV genotype 2 (HPgV/2) was prevalent among both Argentine injecting drug users and pregnant women, in contrast to HPgV/3 observed among pregnant women from Latin American countries with predominant indigenous populations and who had experienced their initial sexual intercourses––and possibly their source of infection––in those countries ( P  < 0.01). In addition, HPgV vertical and horizontal transmission was proven by molecular analysis of E2 gene and construction of identity matrixes with epidemiologically non‐related isolates. This study shows that human migration from neighboring Latin American countries with predominant indigenous populations might contribute to HPgV/3 circulation in Argentina. J. Med. Virol. 86:2076–2083, 2014 . © 2014 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here